Market Overview

Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares

Share:
Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares
Related CRME
Earnings Scheduled For May 15, 2018
14 Stocks Moving In Tuesday's After-Hours Session

CARDIOME PHARMA CORP (NASDAQ: CRME) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million. 

The Analyst

Canaccord Genuity's Dewey Steadman maintains a Buy rating on Cardiome's stock with an unchanged $5 price target.

The Thesis

Cardiome's sale of its Canadian business includes on-market Brinavess and Aggrastat and is complemented by the Xydalba and Trevyent pipeline projects, Steadman said in a Tuesday note. (See the analyst's track record here.) 

Cardiome will form a new company named Correvio and will net the $19 million in cash, which would boost its estimated cash balance to around $40 million, the analyst said. The cash on hand should prove to be sufficient to finance the pharma company's operations through at least 2019, if not longer, he said. 

The divestiture is also an "attractive way" for Cardiome to finance its near-term business development without "sacrificing much upside," given the company's approximately $77,000 in revenue in 2017, the analyst said.

In return, Cipher likely accepted the transaction as it includes Cardiome's roughly $232.5 million in Canadian tax losses that Cardiome would never fully utilize itself.

Cardiome's deal is viewed favorably within the "often-overlooked" specialty pharmaceutical market outside of the U.S, Steadman said. 

Price Action

Shares of Cardiome Pharma were up 3.35 percent at the close Wednesday. 

Related Links:

27 Stocks Moving In Wednesday's Mid-Day Session

Mid-Day Market Update: Crude Oil Up 2.5%; General Mills Shares Plunge

Latest Ratings for CRME

DateFirmActionFromTo
Nov 2017Canaccord GenuityMaintainsBuy
Jul 2017Canaccord GenuityAssumesBuy
Dec 2016Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for CRME
View the Latest Analyst Ratings

Posted-In: Aggrastat Brinavess Canaccord Genuity CanadaAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (CRME)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
APTIJefferiesDowngrades38.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Previewing The Tech Sector As Earnings Season Looms

Esports Continue To Become More Mainstream And a Bigger Part Of The Gaming Industry